Johnson & Johnson (NYSE:JNJ) disclosed that Elizabeth Forminard, Executive Vice President and Chief Legal Officer, sold 13,072 shares of common stock on November 12, 2026, at a price of $284.39 per share, for a total transaction value of $3,717,546.
The sale followed the exercise of employee stock options, through which Forminard acquired the same number of shares at $151.41 per share, amounting to $1,979,231. The options were granted under the company’s Long-Term Incentive Plan and became exercisable on the third anniversary of their grant date.
After these transactions, Forminard directly holds 16,994 shares of Johnson & Johnson common stock.
The insider sale occurs against a backdrop of several notable developments for the healthcare giant. The U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma. The approval is based on data from the Phase 1b/2 OrigAMI-4 trial and will result in Genmab receiving royalties of 8% to 10% of net sales from the drug.
Separately, merger discussions between Smith & Nephew and Johnson & Johnson’s orthopaedics division have collapsed due to disagreements over leadership roles in the proposed combined entity.
Analyst sentiment is mixed. Erste Group downgraded Johnson & Johnson’s stock rating to hold from buy, citing limited upside potential due to valuation concerns. In contrast, TD Cowen reiterated a Buy rating, highlighting the U.S. launch of Shockwave’s C2 Aero Fly catheter as a factor bolstering Johnson & Johnson’s position in the coronary IVL market.
These developments reflect a mix of strategic challenges and opportunities for Johnson & Johnson.